GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advanced Proteome Therapeutics Corp (FRA:0E81) » Definitions » E10

Advanced Proteome Therapeutics (FRA:0E81) E10 : €0.00 (As of Apr. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Advanced Proteome Therapeutics E10?

Note: As E10 is a main component used to calculate Shiller PE Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation sectione below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Advanced Proteome Therapeutics's adjusted earnings per share data for the three months ended in Apr. 2023 was €0.000. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €0.00 for the trailing ten years ended in Apr. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-06-24), Advanced Proteome Therapeutics's current stock price is €0.0005. Advanced Proteome Therapeutics's E10 for the quarter that ended in Apr. 2023 was €0.00. Advanced Proteome Therapeutics's Shiller PE Ratio of today is .


Advanced Proteome Therapeutics E10 Historical Data

The historical data trend for Advanced Proteome Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advanced Proteome Therapeutics E10 Chart

Advanced Proteome Therapeutics Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.11 -0.05 -0.06 - -

Advanced Proteome Therapeutics Quarterly Data
Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -0.07 -0.04 -

Competitive Comparison of Advanced Proteome Therapeutics's E10

For the Biotechnology subindustry, Advanced Proteome Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advanced Proteome Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Advanced Proteome Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Advanced Proteome Therapeutics's Shiller PE Ratio falls into.



Advanced Proteome Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Advanced Proteome Therapeutics's adjusted earnings per share data for the three months ended in Apr. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Apr. 2023 (Change)*Current CPI (Apr. 2023)
=0/123.5712*123.5712
=0.000

Current CPI (Apr. 2023) = 123.5712.

Advanced Proteome Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201307 0.000 97.261 0.000
201310 0.000 97.182 0.000
201401 -0.147 97.261 -0.187
201404 0.013 98.920 0.016
201407 0.074 99.315 0.092
201410 -0.009 99.473 -0.011
201501 -0.017 98.209 -0.021
201504 -0.026 99.710 -0.032
201507 0.000 100.579 0.000
201510 -0.010 100.500 -0.012
201601 -0.013 100.184 -0.016
201604 -0.011 101.370 -0.013
201607 -0.055 101.844 -0.067
201610 -0.013 102.002 -0.016
201701 -0.017 102.318 -0.021
201704 -0.014 103.029 -0.017
201707 -0.046 103.029 -0.055
201710 -0.009 103.424 -0.011
201801 -0.036 104.056 -0.043
201804 0.024 105.320 0.028
201807 -0.022 106.110 -0.026
201810 -0.017 105.952 -0.020
201901 0.009 105.557 0.011
201904 -0.002 107.453 -0.002
201907 -0.012 108.243 -0.014
201910 -0.001 107.927 -0.001
202001 -0.009 108.085 -0.010
202004 -0.005 107.216 -0.006
202007 -0.009 108.401 -0.010
202010 -0.009 108.638 -0.010
202101 0.001 109.192 0.001
202104 -0.042 110.851 -0.047
202107 0.000 112.431 0.000
202110 0.000 113.695 0.000
202201 0.018 114.801 0.019
202204 -0.009 118.357 -0.009
202207 -0.010 120.964 -0.010
202210 -0.010 121.517 -0.010
202301 -0.009 121.596 -0.009
202304 0.000 123.571 0.000

Add all the adjusted EPS together and divide 10 will get our e10.


Advanced Proteome Therapeutics  (FRA:0E81) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Advanced Proteome Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Advanced Proteome Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Advanced Proteome Therapeutics (FRA:0E81) Business Description

Traded in Other Exchanges
N/A
Address
8337 Eastlake Drive, Suite 104, Burnaby, BC, CAN, V5A 4W2
Advanced Proteome Therapeutics Corp is a biotechnology company. It develops and commercializes a platform to use protein modification technologies to create proprietary human protein pharmaceuticals with therapeutic properties. The company develops anti-cancer drugs for cancerous tumors that will destroy a cancer patient's tumor cells selectively, sparing healthy cells. All the operations of the organization are principally carried out in the United States.

Advanced Proteome Therapeutics (FRA:0E81) Headlines

No Headlines